Join the fight to achieve global malaria elimination targets
Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Antenatal corticosteroids (ACS) are administered to pregnant women at risk of preterm birth, to improve health outcomes for the preterm newborn. To address a lack of evidence for this important intervention in low-resource hospitals, WHO established an international research collaboration to conduct hospital-based, placebo-controlled efficacy trials of ACS (dexamethasone) in Bangladesh, India, Kenya, Nigeria and Pakistan. This collaboration recently completed the WHO ACTION-I Trial, which showed that dexamethasone (a corticosteroid) is safe and effective for this indication.
This follow-up study will establish the additional economic evidence required for the adoption of ACS in health benefits packages. Specifically, we will address the following aims:
We will assemble cost data from hospitals that participated in the ACTION-I Trial, and combine this with effectiveness estimates reported in the trial.
This study will provide important evidence to support implementation of ACS in LMICs, including: updating related WHO recommendations, including ACS in health benefits packages, informing policy-makers about cost-effectiveness and affordability of ACS, and facilitating efficient implementation by identifying key cost drivers.
For any general enquiries relating to this project, please contact:
Principal Research Fellow